Viatris Inc. (VTRS) Acquires Aculys Pharma, Inc

​Viatris Inc. (NASDAQ:VTRS) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 15, Viatris Inc. (NASDAQ:VTRS) announced completing the acquisition of Aculys Pharma, Inc., which is a clinical-stage biopharmaceutical company.

​Aculys Pharma, Inc. is commercializing innovative treatments for neurological conditions. Management noted that, as a result of this acquisition, Viatris Inc. (NASDAQ:VTRS) has received rights to develop and commercialize Pitolisant and Spydia, which are two important assets in the Central Nervous System therapy area. Moreover, the company also gained rights for Spydia Nasal Spray in Japan and certain Asia-Pacific regions, which was approved for Japan in 2025.

On the same day, Truist initiated coverage of Viatris Inc. (NASDAQ:VTRS) with a Buy rating and a $15 price target. The firm said they see an affirmative change in the company’s direction under the new leadership. Moreover, the firm also likes the company’s market leading portfolio, progressive foothold in the generics and its robust pipeline.

​Viatris Inc. (NASDAQ:VTRS) is a biotechnology company with a diverse portfolio of therapies spread across a range of therapeutic areas.

While we acknowledge the potential of VTRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.